Pharvaris N.V. (PHVS) Stock Price, Quote & News

Company Profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 tria...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 712036410

Website: pharvaris.com

Address:

Grafenauweg 8, Zug, Switzerland

BioTechHealthX Jul. 19 at 3:38 AM

$PHVS Pharvaris NV is targeting a massive untapped opportunity with its oral HAE therapy. Here’s why early investors are buying in. https://biotechhealthx.com/biotech-news/pharvaris-phvs-the-300m-biotech-that-could-be-the-next-big-thing-in-pharma/

0 · Reply

StockScanners Jul. 15 at 2:49 AM

$PHVS Reached 26.33

0 · Reply

AssAndMoney Jul. 14 at 7:02 PM

$PHVS buy the dip. Thank me later

0 · Reply

AssAndMoney Jul. 14 at 12:57 AM

$PHVS ez money

0 · Reply

StockScanners Jul. 11 at 10:57 PM

$PHVS Keep watch if this holds above 23

0 · Reply

GamBino_MaF187 Jul. 11 at 8:06 PM

$PHVS damm...i was watching this today and didnt get in. I thought the data read out was being delayed ???

0 · Reply

BigSqueezeComing Jul. 10 at 11:15 AM

$PHVS Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 By Pharvaris N.V. | July 10, 2025, 6:50 AM

0 · Reply

JarvisFlow Jul. 7 at 11:30 AM

Wedbush has updated their rating for Pharvaris ( $PHVS ) to Outperform with a price target of 27.

0 · Reply

topstockalerts Jul. 4 at 5:43 PM

$PHVS what’s your target for next week? 🍾....🏦....🍾

0 · Reply

Doozio Jul. 4 at 5:15 PM

$PHVS nope it started out of 🐑⏰♾️ during 🐒🍌🧠⏰♾️. Roger about to rock to da $$$$?

0 · Reply

Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success

Jul 10, 2025, 6:50 AM EDT - 9 days ago

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Jun 27, 2025, 6:50 AM EDT - 22 days ago

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

Jun 16, 2025, 6:50 AM EDT - 4 weeks ago

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

Jun 10, 2025, 6:50 AM EDT - 5 weeks ago

Pharvaris Announces Annual Meeting of Shareholders

Jun 2, 2025, 6:50 AM EDT - 6 weeks ago

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

May 19, 2025, 6:50 AM EDT - 2 months ago

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

May 13, 2025, 4:05 PM EDT - 2 months ago

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 6:50 AM EDT - 2 months ago

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Apr 7, 2025, 6:58 AM EDT - 3 months ago

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Apr 1, 2025, 6:50 AM EDT - 3 months ago

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Mar 3, 2025, 6:50 AM EST - 4 months ago

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Mar 3, 2025, 6:48 AM EST - 4 months ago

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Jan 13, 2025, 6:50 AM EST - 6 months ago

Pharvaris Outlines 2025 Strategic Priorities

Nov 13, 2024, 4:10 PM EST - 8 months ago

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Nov 12, 2024, 6:50 AM EST - 8 months ago

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Oct 16, 2024, 6:50 AM EDT - 9 months ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Oct 15, 2024, 6:50 AM EDT - 9 months ago

Pharvaris to Host Virtual Investor Event on October 23, 2024

Oct 3, 2024, 6:50 AM EDT - 10 months ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Sep 5, 2024, 6:50 AM EDT - 11 months ago

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Sep 5, 2024, 6:49 AM EDT - 11 months ago

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Sep 5, 2024, 6:48 AM EDT - 11 months ago

Pharvaris Presents Data at the Bradykinin Symposium 2024

Aug 28, 2024, 6:50 AM EDT - 11 months ago

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Aug 14, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 4, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

May 13, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

May 8, 2024, 4:10 PM EDT - 1 year ago

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 10, 2024, 4:10 PM EDT - 1 year ago

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 10, 2024, 4:08 PM EDT - 1 year ago

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Apr 4, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Mar 18, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Mar 6, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Mar 5, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Feb 22, 2024, 6:50 AM EST - 1 year ago

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Feb 16, 2024, 6:50 AM EST - 1 year ago

Pharvaris Announces Extraordinary Meeting of Shareholders

Jan 26, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Present at the WSAAI Annual Meeting 2024

Jan 22, 2024, 6:50 AM EST - 1 year ago

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Jan 5, 2024, 6:50 AM EST - 1 year ago

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

Dec 8, 2023, 6:00 PM EST - 1 year ago

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

Dec 6, 2023, 8:12 AM EST - 1 year ago

Pharvaris shares surge as treatment for severe swelling meets clinical trial goal

Dec 6, 2023, 7:02 AM EST - 1 year ago

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

Dec 6, 2023, 6:50 AM EST - 1 year ago

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Nov 30, 2023, 6:50 AM EST - 1 year ago

Pharvaris to Present at the GA²LEN UCARE Conference 2023

Nov 15, 2023, 6:50 AM EST - 1 year ago

Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

Nov 9, 2023, 11:00 AM EST - 1 year ago

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

Nov 2, 2023, 6:50 AM EDT - 1 year ago

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 30, 2023, 6:50 AM EDT - 1 year ago

Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

Oct 13, 2023, 6:50 AM EDT - 1 year ago

Pharvaris To Present at the APAAACI 2023 International Conference

Oct 4, 2023, 7:34 AM EDT - 1 year ago

Pharvaris To Present at the CIIC Fall 2023 Conference

Sep 19, 2023, 6:50 AM EDT - 1 year ago

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

BioTechHealthX Jul. 19 at 3:38 AM

0 · Reply

StockScanners Jul. 15 at 2:49 AM

$PHVS Reached 26.33

0 · Reply

AssAndMoney Jul. 14 at 7:02 PM

$PHVS buy the dip. Thank me later

0 · Reply

AssAndMoney Jul. 14 at 12:57 AM

$PHVS ez money

0 · Reply

StockScanners Jul. 11 at 10:57 PM

$PHVS Keep watch if this holds above 23

0 · Reply

GamBino_MaF187 Jul. 11 at 8:06 PM

$PHVS damm...i was watching this today and didnt get in. I thought the data read out was being delayed ???

0 · Reply

BigSqueezeComing Jul. 10 at 11:15 AM

$PHVS Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 By Pharvaris N.V. | July 10, 2025, 6:50 AM

0 · Reply

JarvisFlow Jul. 7 at 11:30 AM

Wedbush has updated their rating for Pharvaris ( $PHVS ) to Outperform with a price target of 27.

0 · Reply

topstockalerts Jul. 4 at 5:43 PM

$PHVS what’s your target for next week? 🍾....🏦....🍾

0 · Reply

Doozio Jul. 4 at 5:15 PM

$PHVS nope it started out of 🐑⏰♾️ during 🐒🍌🧠⏰♾️. Roger about to rock to da $$$$?

0 · Reply

TacticalGeese Jun. 28 at 5:03 PM

$PHVS

0 · Reply

BigSqueezeComing Jun. 27 at 12:51 PM

$PHVS Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit By Pharvaris N.V. | June 27, 2025, 6:50 AM

0 · Reply

Love_To_Learn Jun. 27 at 10:45 AM

$SOUN using old $PHVS 9.93 9.96 9.97 old Porsche models years ago and where they r now meshing the gaps 10.29/10.31 is also me for good reason this is old $NVCN pop rs pop from 2.19/2.21

0 · Reply

G101SPM Jun. 11 at 6:28 PM

#SHOWTIME European Academy of Allergy and Clinical Immunology Congress (June 12-15) Scheduled to appear: $JSPR, $PHVS, $UPB

0 · Reply

BiotechBonesaw Jun. 9 at 2:03 PM

$KALV - Kalvista is still a buy ahead of their PDUFA $PHVS - Pharvaris is a hold well ahead of their HAE activity in 2026 $PHAR - I would sell or avoid this. Pharming will likely lose market shares or valuation with Kalvista’s expected approval & continued rise

1 · Reply

jpatelyash Jun. 3 at 6:53 PM

🚀 Big catalyst day coming up on June 4th! 📅 Looks like $AKRO and $PHVS both have major Phase 3 data readouts ahead: $AKRO is expecting results for EFX targeting MASH (metabolic dysfunction-associated steatohepatitis) – market cap $4.09B, solid POA at 65%. $PHVS has Deucrictibant data readout for hereditary angioedema (HAE) – smaller cap at $964M but higher POA at 75%! Who’s watching these closely? Are you bullish or bearish? 📈🐂🐻 Let’s discuss your predictions in comments! #biotech #stocks #investing #FDA #catalyst #AKRO #PHVS

1 · Reply

BiotechBonesaw Jun. 3 at 2:47 PM

$PHAR surprised this is running up ahead of $KALV approval in HAE. GLL biotech investors but I would avoid PHAR $ $PHVS until Kalvista does their thing

1 · Reply

DonCorleone77 Jun. 2 at 10:56 AM

$PHVS Pharvaris presents data supporting ongoing clinical development of deucrictibant Pharvaris announced a summary of data that were presented at the 14th C1-Inhibitor Deficiency and Angioedema Workshop. "Additional analyses of deucrictibant data demonstrate consistency in the clinical profile shown in both the prophylactic and on-demand treatment settings," said Berndt Modig, Chief Executive Officer of Pharvaris. "Deucrictibant's early-onset and durable treatment response in the on-demand setting, the maintenance of attack reduction for over a year and a half in the prophylactic setting, and the potential for deucrictibant to be used together in both the prophylactic and on-demand settings, if needed, provide additional evidence of deucrictibant's potential in the treatment of bradykinin-mediated angioedema. Pharvaris continues to diligently execute on the deucrictibant clinical program and is planning for two pivotal data readouts in the next 18 months."

0 · Reply

JarvisFlow May. 14 at 2:34 PM

Cantor Fitzgerald updates rating for Pharvaris ( $PHVS ) to Overweight, target set at 28 → 25.

0 · Reply

Love_To_Learn May. 12 at 8:20 PM

$PHVS u will b impacted by RGTI

0 · Reply

Armonica423 May. 6 at 5:36 PM

$PHVS CYDY

0 · Reply

Armonica423 May. 6 at 5:33 PM

$PHVS. . CYDY

0 · Reply

Market Cap	1.24B
Revenue (ttm)	0.00
Net Income (ttm)	-145.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	24,100
Avg Vol	62,374
Day's Range	N/A - N/A
Shares Out	52.29M
Stochastic %K	65%
Beta	-2.82
Analysts	Strong Sell
Price Target	$32.38